acute coronary syndrome
Conditions
Interventions
Standard dual antibody group(A):Oral standard dose and time of dual antiplatelet drugs
Standard dose ticagrelor monoclonal antiplateletStandard dose tigrilol monoclonal antiplatelet:The duration of dual antiplatelet therapy was shortened to standard dose ticagrelor monoclonal antiplatel
Low dose ticagrelor monoclonal antiplatelet(C):The duration of dual antiplatelet therapy was shortened to low dose ticagrelor monoclonal antiplatelet therapy
Sponsors
Tianjin Union Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) aged =18 years, regardless of gender; 2) patients clinically diagnosed with acute coronary syndrome (ACS) who were treated with dual-antibody therapy (aspirin 75-100mgqd + tigrilol 90mgBID) for 6-9 months after PCI; 3) able and willing to sign informed consent and abide by the research protocol.
Exclusion criteria
Exclusion criteria: 1) patients with high risk of ischemia, such as patients with left main disease implanted with stents, patients with double-vessel disease implanted with stents, and patients with dual-antibody ischemia symptoms (chest tightness, chest pain, etc.) who persist 6-9 months after PCI and whose electrocardiogram indicates new ischemia manifestations; 2) patients allergic to aspirin or tigrilol; 3) any of the following is true: cardiac shock, chronic congestive heart failure NYHA class III or higher, ultrasonic cardiac graphic left ventricular ejection fraction < 35%, low blood pressure (< 90 MMHG systolic or diastolic blood pressure < 60 MMHG), severe arrhythmia (including height of atrioventricular block, sick sinus syndrome, sustained ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, liver function is (not a heart disease caused the ALT and AST 3 times more than normal ceiling), severe renal insufficiency (eGFR < 30 ml/min), cirrhosis of the liver; 4) life expectancy of patients with other serious diseases <1 year; 5) patients with mental disorder or alcohol dependence who cannot have good compliance; 6) patients using thrombolytic or anticoagulant drugs; 7) inability to discontinue non-selective non-steroidal anti-inflammatory drugs (except aspirin) and prostacyclin or other drugs that may affect coagulation function; 8) positive pregnancy test results of women of reproductive age during screening; 9) women who have the intention to become pregnant or are breast-feeding in the study; 10) those who are receiving any experimental drugs or medical devices before screening; 11) patients who plan to undergo surgery in the past three months; 12) the patient is not willing to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet aggregation rate;Urinary content of 11- dehydrothromboxane B2(11 dh - TXB2); | — |
Countries
China
Contacts
Public ContactZhuhua Yao
Tianjin Union Medical Center
Outcome results
None listed